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ABSTRACT   
Systemic lupus erythematosus (SLE) is a challenge for pediatricians 
due to the heterogeneity of its clinical manifestations and the rarity 
of the disorder in this age group. Neuropsychiatric SLE (NPSLE) 
was defined especially in adult patients and the clinical course of 
this manifestation is still not clearly defined in the pediatric age 
group. We, here report a five-year old girl presenting with extensive 
maculopapular skin lesions, oral ulcers and neuropsychiatric 
symptoms. She had elevated titers of anti-nuclear antibody 
(ANA), Anti-ds-DNA, anti-histone antibodies and complement 
levels. Serum coxsackie and cytomegalovirus (CMV) IgM tests 
were positive, as well. Magnetic resonance imaging (MRI) of 
the brain demonstrated extended cerebral and cerebellar atrophy. 
Pediatricians should be attentive to the possibility of neurolupus 
for patients with neurological problems despite a young age at 
presentation. Appropriate therapy is a challenging task.  
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ÖZET
Sistemik lupus eritromatözis (SLE) çocukluk çağında nadir 
görülmesinin yanında, değişik klinik bulgular ile karşımıza 
çıkabilmekte ve bu nedenle tanı konulmasında zorluk 
yaşanmaktadır. Nörolupus erişkin hastalarda daha iyi tanımlanmış 
klinik tablo iken, çocuk yaş grubunda daha nadir olarak görülür. 
Beş yaşında kız hasta, yaygın makülopapüler cilt lezyonları, 
oral ülser, nöropsikiatrik semptomlar ile kliniğimize başvurdu. 
Antinüklear antikor (ANA), Anti-ds-DNA ve anti-histon antikor 
poztifliğinin yanında, kompleman değerlerinde düşüklük 
saptandı. Serum coxsackie ve sitomegalovirus  (CMV) IgM 
testleri eş zamanlı pozitif bulundu. Kraniyal magnetik rezonans 
görüntüleme (MRG)’de serebral ve serebellar atrofi gözlendi. Bu 
olgu sunumuyla, erken dönemde nörolojik bulgular ile SLE’nin 
klinikte karşımıza çıkabileceği ve viral enfeksiyonların hastalığın 
patogenezinde rol alabileceği hatırlatılmak istenmiştir. 
Anahtar kelimeler: Nöropsikiyatrik lupus, Çocuk, CMV, 
Coxsackie
Introduction 
Systemic lupus erythematosus (SLE) is a chronic 
autoimmune disease with various system manifestations 
characterized by episodes of flares and remissions. The 
median age at onset of symptoms in pediatric SLE is between 
11-12 years, with a female predominance being pronounced 
after puberty [1]. Neuropsychiatric manifestations can occur 
in 22-95% of pediatric cases, being much less frequent as 
an initial presenting symptom [2]. Symptoms of central 
nervous system (CNS) involvement range from poor school 
performance, depressive moods and difficulty to concentrate 
up to seizures, psychosis and stroke. The presence of specific 
antibodies to neurons, or intracytoplasmic parts of neurons 
(anti ribosomal P, anti Ro; SS-A or anti-La; SS-B) may 
support CNS involvement [3]. 
A role in the occurrence or the exacerbation of SLE has 
been suggested for infections with various viral pathogens 
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including Epstein-Barr virus (EBV), cytomegalovirus 
(CMV) and parvovirus B19 [4]. However, an argument 
concerning the mechanisms involved is unresolved. 
We, hereby describe a 5-year-old girl with an atypical 
presentation of neuropsychiatric SLE.  
Case  Report
A five-year-old girl was admitted to our hospital showing 
signs of  lethargy, lack of verbal communication, inability 
to walk, loss of sleep and appetite for 2 days. She was 
reported to have had a febrile episode and weight loss (8 
kg) during the previous 2 months. The family reported skin 
rashes, which initially appeared on cheeks two months ago, 
with extension to upper and lower extremities including the 
palms and soles; these were unresponsive to topical steroids. 
Physical examination revealed oral ulcers; on the palate, 
buccal mucosa and tongue, in addition to macules and 
papules on cheeks, palms and soles (Figure 1 A-C). Vital 
signs were within the normal range (respiratory rate: 18/min., 
heart rate: 105/min, blood pressure: 92/62 mmHg) except 
for a sub-febrile body temperature (37.8°C). Neurological 
examination at first glance showed irritability, lack of speech 
and eye contact with a depressed mood.  She had bilateral 
spasticity and brisk deep tendon reflexes in the lower 
extremities, ankle clonus and a positive Babinski response. 
Her past medical history revealed normal developmental 
milestones. Biochemical examination revealed leukopenia 
(3100/mm3 (<5000/mm3)), lymphopenia (1100/mm3 
(<1500/mm3)), anemia (Hb: 8.4 mg/dl and MCV: 75 FL) 
and thrombocytopenia (PLT: 65.000/mm3). Acute phase 
reactants were remarkably elevated (ESR: 134 mm/hour, 
CRP: 17 mg/dl (<5 mg/dl)). Coagulation parameters were 
normal. Serum electrolytes and renal function tests were all 
within the normal range while, liver enzymes (AST: 164 IU, 
ALT: 78 IU) were high and serum albumin low (albumin: 2.9 
mg/dl). Urine analyses and sediment showed no proteinuria, 
hematuria or cellular casts at admission. A lumbar puncture 
was performed, showing normal cerebrospinal fluid 
(CSF) protein and glucose levels and negative culture 
(bacterial culture, mycobacterium and fungus) results. CSF 
polymerase chain reaction (PCR) testing for Herpes virus, 
enterovirus and tuberculosis were also negative. Blood 
cultures for aerobic and anaerobic bacteria, Brucella spot 
and Wright agglutination and Quantiferon tests were all 
negative. Serum IgM titers for Herpes virus type I and II, 
enterovirus, parvovirus B19, Ebstein - Barr virus were all 
negative. Meanwhile, antibodies against CMV, coxsackie 
A and B viruses were positive with weak titers. Based on 
these findings, a viral infection was not thought to explain 
the whole clinical picture. Therefore, in  order to search for 
a suspected neurological involvement of SLE autoimmune 
markers were checked. Immune fluorescence assay revealed 
positive ANA dilution at 1/160 titration with a homogenous 
pattern. In addition, rheumatoid factor (134 UI/ml positive 
(<20 UI/ml)), anti-ds DNA and anti-histone antibodies 
were found to be positive. Screening of antiphospholipid 
antibodies including lupus anticoagulant,  the Veneral 
Disease Research Laboratory(VDRL), IgM and IgG tests, 
anticardiolipin, antiphospholipid and anti beta2 glycoprotein 
and anti-Smith antibodies were all negative. Serum 
complement levels were in the low range (C3:0.17 g/L 
(<0.75 g/L), C4:0.03 (<0.1 g/L). A 24-hour urinary protein 
excretion test was performed, with a normal result (3.8 mg/
m2/hr) initially, which turned out be elevated in the following 
week (20 mg/m2/hr). Magnetic resonance imaging (MRI) 
of brain showed diffuse cerebral and cerebellar atrophy, 
whereas MRI angiography and diffusion were within normal 
limits (Figure 2). Minimal left ventricular dilatation without 
effusion was detected in echocardiography in the presence 
of a normal cardiothoracic ratio, electrocardiogram and CK-
MB. A renal biopsy revealed type 4 diffuse proliferative 
glomerulonephritis. She received pulse methylprednisolone 
treatment at a dose of 30 mg/kg/day for five consecutive 
days, followed by oral prednisone 2mg/kg/day, with a 
Figure 1A-C. Exanthema of the skin A: face, B: palms, C: soles.
107Barış et al.
Early-onset neurolupusMarmara Medical Journal 2015; 28: 105-108
tapering scheme thereafter, the maintenance of which did 
not reveal any significant neurological improvement. At 
that point a high dose intravenous immunoglobulin (1gr/kg/
day for twice) along with cycloposphamide (at a cumulative 
dose of 160 mg/kg) was started. Interestingly, there was a 
prompt improvement in her neurological symptoms right 
after IVIG infusion; she was able to communicate verbally, 
manage comprehensive tasks and maintain an erect position. 
At the end of the 2nd week of treatment the fever and rash 
had subsided, she was able to speak fluently and walk 
with help. In addition to immunosupressive treatment, 
hydroxychloroquine (3mg/kg/day) was used for skin 
involvement. In line with the resolution of clinical findings, 
a decrease in acute phase reactants and increase in serum 
complement levels were noted. 
Discussion
Neuropsychiatric SLE (NPSLE) refers to neurological and 
psychiatric syndromes occurring in patients with lupus at any 
time during the course of the disease, not attributable to other 
causes [5]. The condition is considered in the differential 
diagnosis of many conditions in pediatric practice. Among 
the diagnostic procedures autoantibodies serve only as clues 
in addition to nonspecific findings in neurological imaging. 
Since no single test is diagnostic for NPSLE, the clinician 
should be extremely careful at the initial evaluation to look 
for any possible neurological symptoms, which may be 
quite subtle. Depending on the part of the CNS involved, 
symptoms and manifestations are variable and can occur in 
22-95% of pediatric cases. However,  they are rare as an 
initial presenting complaint [2, 6]. Our patient, five-year 
old female, is interesting in that her disease started at quite 
an early age. Despite vigorous treatment, the response was 
partial, with some neurological sequela.  
In the absence of a high index of suspicion, detection of 
IgM antibodies to coxsackie A, B and CMV in the setting 
of a presentation suggestive of a viral illness might have 
obscured the diagnosis of lupus at the outset. This finding 
per se, obviously, is not likely to explain the whole clinical 
picture. In this patient, however, it is not known whether 
this finding  had an implication in terms of a possible role 
of these viruses in the induction or aggrevation of the 
immune process or simply related to cross-reactivity with 
high levels of rheumatoid factor [7].  
It has been suggested that several factors including 
vasculitis, apoptosis, production of autoantibodies to 
neuronal antigens, to ribosomes or phospholipids and 
inflammations secondary to the local cytokine production 
play role in the pathogenesis of neuropsychiatric SLE. 
Specific antibodies directed at neurons and intracytoplasmic 
parts of neurons (anti-ribosomal P, anti Ro; SS-A or anti-
La; SS-B) may be related to CNS involvement [3].  It 
is noteworthy that these antibodies in our patient were 
negative. 
Recently, systemic or chilblain lupus manifesting in 
early childhood have been reported. These were caused 
by heterozygous mutations in the genes encoding 3’ repair 
exonuclease (TREX1) or the phosphohydrolase sterile 
alpha motif domain and HD domain containing protein 1 
(SAMHD1). TREX1 is the major intracellular DNase with 
specificity for single-stranded DNA. TREX1 deficiency 
leads to an accumulation of intracellular nucleic acids. 
It is hypothesized that these nucleic acids act as danger 
signals and activate innate immune sensors, leading to a 
type 1 interferon response that favors the development 
of autoimmunity. Biallelic or heterozygous de novo 
TREX1 mutations cause Aicardi Goutieres syndrome, an 
inflammatory leukoencephalopathy that features signs of 
systemic autoimmunity [8, 9]. For this reason, cutaneous or 
systemic lupus findings with early onset should be thought 
of as type 1 interferonopathies. In this regard, we plan to 
investigate the  causative gene mutation in our patient.  
In patients with pediatric lupus with a younger onset 
anti-ribosomal antibodies have previously been found to be 
specifically associated with depression and psychosis [10]. 
Although,  lympho-cytotoxic antibodies (LCAs) have been 
suggested as a marker in patients especially with cognitive 
and visual spatial defects [11] none of these qualified  as  a 
diagnostic test for neuropsychiatric SLE in current practice. 
In addition to these markers, marked lymphopenia was 
mentioned as an independent risk factor associated with a 
neuropsychiatric manifestation, and this was also apparent 
in our patient at the initial presentation [12]. The role of 
advanced neuroimaging modalities such as single photon 
Figure 2A-B. Atrophy of A: the cerebrum and B: the cerebellum 
on the magnetic resonance imaging of the brain. 
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emission computed tomography (SPECT) to uncover 
structural and metabolic abnormalities in brain regions 
having a  normal appearance on conventional MRI has also 
been examined, but with no further assistance in diagnosis 
or prognosis of neurolupus [13]. 
Atypical manifestations of SLE at presentation and 
early onset kidney or CNS diseases have been associated 
with poor outcomes [14]. Hence, the management of 
patients with lupus nephritis or NPSLE includes aggressive 
immunosuppressive therapy. For refractory NPSLE, 
intravenous immunoglobulin, plasmapheresis, and rituximab 
have been used successfully [15, 16]. Indeed, the patient 
presented here initially received five cycles of pulsed steroid, 
with no significant improvement. Interestingly, a prompt 
response in CNS symptoms was achieved by the infusion 
of a high dose IVIG.  Meanwhile, nephritis was treated with 
long term steroids and concomitant cyclophosphamide.
In conclusion, SLE in a young child presenting with 
neurological symptoms is unusual, and can only be 
diagnosed on the basis  of a  high index of suspicion. A 
watchfull monitoring  with serial clinical examinations 
can uncover subtle alterations which aid in making the 
diagnosis. High doses of IVIG in our patient appeared 
beneficial for the neurological symptoms, which had 
responded poorly to conventional therapy.  The optimal 
treatment strategies for this rare disease in childhood 
deserve further attention. 
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